Truvada ([emtricitabine + tenofovir disoproxil fumarate (TDF)]; Gilead/Japan Tobacco) is a once-daily, fixed-dose combination of two of Gilead’s marketed nucleoside reverse transcriptase inhibitors (NRTIs): Emtriva (emtricitabine) and Viread (tenofovir disoproxil fumarate [TDF]). NRTIs block the action of the viral reverse transcriptase enzyme, preventing synthesis of viral DNA and subsequently inhibiting viral replication.
Truvada was the standard-of-care nucleos(t)ide reverse transcriptase inhibitor backbone for HIV-1 therapy for over a decade, but has now been largely replaced for the treatment of HIV by the successor NRTI backbone Descovy ([emtricitabine + tenofovir alafenamide (TAF)]; Gilead/Japan Tobacco), which possesses reduced renal and bone toxicity. Truvada’s sales have also been negatively impacted by the launch of generics in the EU from September 2017, with EU sales falling from $644m in 2017 to $260m in 2018.
4 Drug Overview
5 Product Profiles
5 Truvada : HIV
LIST OF FIGURES
10 Figure 60: Truvada sales for HIV across the US and five major EU markets, by country, 2018–27
11 Figure 61: Datamonitor Healthcare’s drug assessment summary of cabotegravir/rilpivirine for HIV
13 Figure 62: Datamonitor Healthcare’s drug assessment summary of cabotegravir/rilpivirine for HIV
LIST OF TABLES
6 Table 1: Truvada drug profile
7 Table 2: Approval history of Truvada for HIV in the US, Japan, and five major EU markets
8 Table 3: Late-phase trials of Truvada for HIV
9 Table 4: Truvada for HIV – SWOT analysis
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.